Financial Performance - Net sales decreased to $39245 thousand in Q2 2025 from $54793 thousand in Q2 2024 [23] - Adjusted Gross Profit decreased to $7531 thousand in Q2 2025 from $13349 thousand in Q2 2024 [23] - Adjusted Gross Profit Margin decreased to 192% of net sales in Q2 2025 from 244% in Q2 2024 [23] - Adjusted SG&A increased to 250% of net sales in Q2 2025 from 212% in Q2 2024, while the actual expense decreased to $9803 thousand from $11624 thousand [23] - Adjusted EBITDA decreased to $(2272) thousand in Q2 2025 from $1725 thousand in Q2 2024 [23] Strategic Initiatives and Restructuring - A new restructuring plan was initiated to optimize the product portfolio, distribution center, and manufacturing footprint [13, 16] - The company anticipates over $3 million in estimated annual cost savings from the restructuring plan, along with improvements in working capital [16] - The company is focused on higher-margin proprietary brands by eliminating underperforming brands [16] - The company expects improved Adjusted Gross Profit Margin and reduced year-over-year Adjusted SG&A expense for full year 2025 [20] Liquidity and Debt - Cash balance as of June 30, 2025, was $110 million [30] - Liquidity, defined as cash plus available borrowing capacity, was $200 million as of June 30, 2025 [30] - Free Cash Flow for the three months ended June 30, 2025, was $14 million [30] - Total debt outstanding as of June 30, 2025, was $1226 million, with net debt at $1116 million [30]

Financial Performance & Growth - TAT Technologies reported Q2 2025 revenue of $43.1 million, an 18% increase year-over-year compared to $36.5 million in Q2 2024 [41] - Gross profit for Q2 2025 was $10.8 million, a 36% increase from $8.0 million in Q2 2024 [41] - Operating income increased by 62% to $4.4 million in Q2 2025, compared to $2.7 million in Q2 2024 [41] - Adjusted EBITDA for Q2 2025 was $6.1 million, a 39% increase from $4.3 million in Q2 2024, with an Adjusted EBITDA Margin of 14.0% [41] - The company's backlog reached $524 million in Q2 2025 [23] Revenue Diversification - Heat Exchange revenue was $17.7 million in Q2 2025, representing a 12% year-over-year increase [97] - APU revenue was $11.5 million in Q2 2025, a 7% increase year-over-year [97] - Trading & Leasing revenue experienced significant growth, reaching $5.9 million in Q2 2025, a 201% increase compared to Q2 2024 [97] Balance Sheet - Shareholder's equity stood at $165.8 million in Q2 2025 [106] - Total assets amounted to $213.6 million in Q2 2025 [106] - Operating working capital was $93.1 million in Q2 2025 [106]

Anaphylm (Epinephrine) Sublingual Film - FDA accepted the NDA for Anaphylm in Q2 2025, with a PDUFA date scheduled for January 31, 2026[8] - The company is preparing for a U S launch of Anaphylm in Q1 2026, pending FDA approval[8] - A pediatric study showed that 12 mg Anaphylm administration demonstrated comparable PK curves in adult and pediatric subjects, with no statistical differences between PK parameters[16] - Pharmacodynamic (PD) outcomes in the pediatric study showed a positive inflection for Heart Rate (HR), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) after Anaphylm exposure[25] Financial Performance and Outlook - As of June 30, 2025, the company had a cash balance of approximately $60.5 million[8] - The company projects its cash runway into 2026[8] - The company is guiding for total revenues of approximately $44-$50 million for 2025[34] - The company anticipates a Non-GAAP adjusted EBITDA loss of approximately $47-$51 million for 2025[34] Manufacturing Operations - Manufacturing operations continue to generate cash[30] - Doses shipped in Q2 2025 were 37204 (thousands)[31]

Investment Highlights - Bicara Therapeutics is advancing ficerafusp alfa (FICERA), a bifunctional EGFR-directed antibody x TGF-β ligand trap, designed to enable tumor penetration by breaking barriers in the tumor microenvironment to drive deep and durable responses[8, 125] - FICERA + pembro offers a potential new 1L therapy for HPV-negative R/M HNSCC, with the FORTIFI-HN01 Ph 2/3 trial ongoing and enrolling[8, 125] - The company has a robust financial position with approximately $437 million in cash and equivalents[8, 125] Clinical Trial & Market Opportunity - There is a significant market opportunity with approximately 23,000 cases of R/M HNSCC annually in the U S, and a significant unmet need for better treatment options (13% 5yr survival)[8, 33, 125] - In a Ph 1b trial of FICERA + Pembrolizumab in HPV-neg, CPS≥1 1L R/M HNSCC, the confirmed ORR was 54% (15/28)[60, 75] - The same trial showed a median PFS of 9 9 months and a median OS of 21 3 months, with a 2-year OS rate of 46%[66, 72, 75] - The median DOR was 21 7 months, with DOR rates of 79% at 6 months, 65% at 12 months, and 57% at 18 months[69, 75] Expansion Opportunities - The company is expanding into other squamous cell carcinomas and solid tumors, with encouraging clinical activity observed in Ph 1b expansion cohorts to date[8, 125] - In 2L+ cutaneous squamous cell carcinoma (cSCC), FICERA monotherapy showed an ORR of 30% (7/23) and a mPFS of 7 0 months in PD-1-refractory patients[114] - In 2L+ squamous cancer of the anal canal (SCAC), FICERA + pembro showed a 25% ORR (7/28) and a 12-month PFS rate of 40 7%[118]

Financial Performance & Growth - Harrow expects 2025 revenue to be more than $280 million[9] - In Q2 2025, Adjusted EBITDA was $17006 thousand[16] - Harrow had $52963 thousand in cash and cash equivalents as of June 30, 2025[17] Product Portfolio & Market Position - VEVYE showed 66% Q/o/Q Rx volume growth[10, 34] - VEVYE captured 78% of the total DED market in Q2 2025, an increase of 26% from Q1 2025[39] - IHEEZO experienced 25% growth in unit demand in Q2 2025 vs Q1 2025[10] - TRIESENCE showed 32% growth in Q2 2025 vs Q1 2025, with Q4 2025 expansion to a new market[10] Strategic Initiatives & Acquisitions - Harrow expanded the VAFA program capacity with a strategic alliance with Apollo Care in August 2025[9] - Harrow acquired the exclusive U S rights to Samsung Bioepis ophthalmology biosimilars pipeline, including BYOOVIZ (Lucentis) & OPUVIZ (Eylea) in July 2025[9] - Harrow acquired the exclusive U S commercial rights for BYQLOVI in June 2025, planning a launch in Q1 2026[9, 46]

Third Quarter FY 2025 Earnings Call Presentation August 12, 2025 Hillenbrand Call Participants Trent Schwartz Executive Director, IR Kim Ryan President & CEO Megan Walke VP & Interim CFO Disclosure Regarding Forward-Looking Statements Throughout this earnings presentation, we make a number of "forward-looking statements," including statements that are within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private S ...

Key Highlights & Growth - Pony AI produced over 200 Gen-7 vehicles as of August 11, 2025 [7] - The company aims to produce over 1,000 vehicles by the end of 2025 [7, 22] - Registered user growth increased by 136% year-over-year from 2Q24 to 2Q25 [7, 32] - Total revenue grew by 76% in 2Q25 [7] - Fare-charging revenue experienced a growth of over 300% in 2Q25 [7, 35, 70] Commercialization & Operations - Pony AI is the only company with fully driverless commercial licenses in all four Tier-1 cities in China (Beijing, Shanghai, Guangzhou, Shenzhen) [20, 31] - Robotaxis receive approximately 15 average daily orders [20] - Accumulated autonomous driving kilometers reached 488 million+ as of June 30, 2025 [36] - Accumulated autonomous driverless kilometers reached 87 million+ as of June 30, 2025 [36] Financial Performance - Robotaxi services revenue increased by 1578% from $06 million in 2Q24 to $15 million in 2Q25 [65] - Total revenue increased by 9018% from $122 million in 2Q24 to $104 million in 2Q25 [69]

Financial Performance - Q2 2025 - Revenue decreased by 18.7% year-over-year to $65.8 million[60] - On a constant currency basis, revenue decreased by 22.5% year-over-year to $62.7 million[62] - IFRS Gross Margin was 0.3%, a decrease of 4.9% year-over-year[60] - Non-IFRS Gross Margin increased to 17.0%, up 3.5% year-over-year[62] - Net Loss was $(26.5) million, a decrease of $6.5 million year-over-year[60] - Adjusted EBITDA increased by 4.2% year-over-year to $12.5 million[62] Operational Metrics - Total riding distance reached 13.2 billion kilometers[53] 2025 Guidance - The company expects revenue to be at the low-end of $295 million - $315 million[65] Additional Points - Operating cash flow was $15.2 million[28] - Operating expenses reduced by 1740%[28]

Q2 2025 Production Update - Earned 718 BTC in Q2 2025[17] - Direct cost per BTC was $48200[17] - Revenue per BTC was $98000[17] - Estimated proceeds of $18 million for reinvestment in the US from Argentina shut-down[18] - Achieved a 5% improvement in direct hashcost[18] Bitcoin Business - Bitcoin holdings are approximately 1200 BTC, up about 25% from year-end 2024[25] - The company's hashrate is 177 EHuM[21] - Mining operations generate approximately $8 million in free cash flow per month[23, 26] Energy Portfolio and HPC/AI Development - The company has a 1 GW energy pipeline in Pennsylvania[28, 42] - The company has a 1 GW data center built in Washington[28] - The company has a 170 MW energy pipeline in Quebec[28] - The company secured $300 million in debt financing from Macquarie Group for initial Panther Creek data center development[47] Financial Highlights - Q2 2025 revenue was $78 million, an increase of 87% year-over-year from $42 million in Q2 2024[49] - Q2 2025 gross mining margin was 43%[50] - Q2 2025 Adjusted EBITDA was $14 million, an increase of 27% year-over-year from $11 million in Q2 2024[53] - The company has approximately $230 million in total liquidity as of August 11, 2025[56]

Financial Performance & Growth - Sparebanken Norge's Q2 2025 presentation highlights strong financial performance and growth following a legal merger on May 2, 2025 [2, 4] - The group's cost-to-income ratio for Q2 2025 is 29%, positioning it favorably compared to peers [8, 9] - The company reported a pro forma Return on Equity (ROE) of 18% for Q2 2025 [16] - Net interest income increased, reaching NOK 2711 million in Q2 2025 [42, 43] - Underlying cost growth is approximately 2.3%, with a pro forma cost-to-income ratio of 29% (27.4% adjusted for merger costs) [49] Lending & Deposits - The company has a gross loans portfolio of NOK 463 billion [11, 12] - Retail customer lending grew by 3.7% year-to-date, while corporate customer lending grew by 5.1% year-to-date [6] - Retail customer deposits show year-on-year growth of 11.2% [36] - Mortgage loan delinquencies (90 days) remain below 0.1% [59] Subsidiaries & Associated Companies - Eiendomsmegler Norge achieved a year-to-date pre-tax profit of NOK 49 million [75] - Borea Asset Management has Assets under Management (AUM) of NOK 18.7 billion [77] - Frende Holding's annualized ROE was 23.6% in the first half of 2025 [83] Capital Adequacy & Synergies - The Common Equity Tier 1 (CET1) ratio is 18.4% [17, 69, 70] - Realized capital synergies of approximately NOK 2 billion in Q2 2025 due to the implementation of CRR3/Basel IV [123] - Cost synergies are estimated to be greater than NOK 425 million [111, 112, 119] Future Targets & Strategy - The company aims for a Return on Equity (ROE) greater than 13% and a CET1 capital ratio greater than 16% by 2026-2028 [112, 129] - Bulder is targeting NOK 83 billion in lending [111] - Borea Asset Management is targeting > NOK 34 billion in AUM by the end of 2028 [195]